March - 20206March - 06 - 2020, volume 04 - Issue 05 Published by ValleyMedia, Inc. Managing EditorAlex D'souzaEditorial StaffVisualizerDavid ParkerScott JuasySalesAndrew D'Souzaandrew.dsouza@medicaltechoutlook.com510.996.5123Contact usEmailPhone:510 230 0396 Fax:510-894-8405sales@medicaltechoutlook.comeditor@medicaltechoutlook.commarketing@medicaltechoutlook.comJoshua Parker Merlin WatsonJoe Philip Laura PintoTo subscribe to MedicalTech OutlookVisit www.medicaltechoutlook.com Copyright © 2020 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffAlex D'souzaManaging Editoreditor@medicaltechoutlook.comWhen it comes to in vitro diagnostic (IVD) technologies, medical device and diagnostic companies have been looking forward to step on the next big innovation. The last few years have seen an upswing in IVD technologies in the market, as device makers expand their knowledge and resources surrounding IVD technologies. Moreover, with new products in the marketplace for direct-to-consumer tests (DTC), point-of-care diagnostics, and next-generation sequencing, consumers may be on the boundary of a new surge of diagnostic technologies that could have an impact on other diagnostic areas, such as gene sequencing and editing. These new IVD technologies could potentially be the key that unlocks the door for a whole new generation of diagnostic possibilities.An essential factor leading the growth of the global in-vitro diagnostics market is the high demand for personalized medicine. The growing focus on next-generation sequencing for genetic mapping of patients, companion diagnostics, whole genome technology, increasing use of combination biomarkers for diagnostics is stoking the growth of the personalized medicine market. With researchers and diagnostic companies in pursuit to develop diagnostic tests for therapeutic application fields such as cardio-renal, neurology, antiviral, pulmonary, and psychiatry, the demand for personalized medicines is expected to grow considerably in the near future.In this edition of MedTech Outlook, we bring to you some of the leading companies that have excelled through innovation in delivering the highest quality of In Vitro Diagnostic Solution. We hope the inspiring success stories of these providers benefit our readers who are in pursuit of an ideal collaboration.Let us know your thoughts!Taking Technology to the Next LevelSarah FernandesEDITORIAL
< Page 5 | Page 7 >